title: Tyrosine kinase inhibitors may change the metastatic pattern.
authors.affiliation: Ankara Numune Education and Research Hospital, Department of Medical Oncology, Ankara, Turkey.
authors.forename: M A N
authors.initials: MA
authors.lastname: Sendur
authors.forename: S
authors.initials: S
authors.lastname: Aksoy
authors.forename: N Y
authors.initials: NY
authors.lastname: Ozdemir
authors.forename: N
authors.initials: N
authors.lastname: Zengin
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000201:enzymology / Q000556:secondary*; D000077192:Adenocarcinoma of Lung; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology*; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000556:secondary*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors